Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study
Without proper regulatory oversight, patients may receive medications with inconsistent potency, contamination, or incorrect ingredients
or medications that also slow gastric motility may face higher risk and should discuss non-oral contraceptive options with their provider
The same caveat that applies to all SLU-PP-332 reports applies here: oral cap users may be reporting placebo, and even injectable users are below mouse-scaled doses
Limits: In the chromatogram of the test solution, if any peak corresponds in retention time to the Impurity I peak, calculate its content by the external standard method using peak areas
Theres no universal answer here